Lexaria’s Phase 1b GLP-1 Study Achieves Important “Last Patient Last Visit” Milestone
KELOWNA, BC – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization (“CRO“) has completed… Read More




